|
INTS9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.96279999984139E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.57370000000357E-05 |
| Normal-vs-Stage2 |
5.984200E-02 |
| Normal-vs-Stage3 |
3.49619999950868E-07 |
| Normal-vs-Stage4 |
1.45120000016874E-07 |
| Stage1-vs-Stage2 |
4.591200E-01 |
| Stage1-vs-Stage3 |
6.592200E-02 |
| Stage1-vs-Stage4 |
3.024000E-02 |
| Stage2-vs-Stage3 |
9.115700E-02 |
| Stage2-vs-Stage4 |
3.399800E-02 |
| Stage3-vs-Stage4 |
4.121200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.27379999956968E-07 |
| Normal-vs-AfricanAmerican |
5.698400E-02 |
| Normal-vs-Asian |
5.784500E-02 |
| Caucasian-vs-AfricanAmerican |
4.839800E-01 |
| Caucasian-vs-Asian |
1.686620E-01 |
| AfricanAmerican-vs-Asian |
7.893600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.16259999999258E-05 |
| Normal-vs-Female |
6.11599999977841E-07 |
| Male-vs-Female |
7.853600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.22410000000539E-05 |
| Normal-vs-Age(41-60Yrs) |
1.77700000003611E-06 |
| Normal-vs-Age(61-80Yrs) |
2.30689999999312E-05 |
| Normal-vs-Age(81-100Yrs) |
4.839500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.969400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.010000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.940000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.401400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.653800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.095800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.464690E-03 |
| Classical-VS-Follicular |
3.488400E-01 |
| Classical-VS-Other |
9.065400E-01 |
| Classical-VS-Normal |
4.05909999999787E-05 |
| Tall-VS-Follicular |
8.007600E-02 |
| Tall-VS-Other |
5.939800E-01 |
| Tall-VS-Normal |
4.27930000324039E-08 |
| Follicular-VS-Other |
9.092400E-01 |
| Follicular-VS-Normal |
1.403000E-04 |
| Other-VS-Normal |
3.843800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.9293999999932E-05 |
| Normal-vs-N1 |
1.55709999999365E-05 |
| N0-vs-N1 |
5.950400E-02 |
|
|
